Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about $10 billion in cash, marking the largest deal in Vertex’s history and expanding the company beyond cystic fibrosis. Vertex will add Palsonify (paltusotine), an approved once-daily oral SST2 agonist for acromegaly, plus atumelnant, an oral ACTH receptor antagonist in phase 3 for congenital adrenal hyperplasia (CAH). The transaction is expected to close in the third quarter of 2026 and includes bridge financing of $4.5 billion committed by Bank of America and Morgan Stanley. Crinetics’ portfolio adds endocrinology as a new commercial pillar for Vertex, alongside its existing specialties. Vertex estimates peak combined sales potential of more than $5 billion for Palsonify and atumelnant, and both boards approved the acquisition unanimously.